Adaptimmune Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Segment reporting (Tables)

Segment reporting (Tables)

3 Months Ended

Mar. 31, 2025

The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):


	Three months ended
	March 31,
	2025		2024
Revenue	$	7,285	$	5,678
Less:
Cost of goods sold		(879)		—
Research		(2,108)		(3,800)
CMC and Quality		(12,085)		(14,200)
Biomarkers		(1,222)		(2,500)
Development and Compliance		(10,550)		(12,600)
Infrastructure management and Facilities		(7,339)		(7,700)
Commercial and Commercial planning		(4,398)		(2,600)
Support and corporate functions		(12,639)		(9,000)
Other segment expenses^(a)		(1,798)		(2,539)
Total operating expenses		(53,018)		(54,939)
Operating loss		(45,733)		(49,261)

Interest income		910		1,345
Interest expense		(1,881)		—
Other income (expense), net		(305)		(61)
Income tax expense		(575)		(526)
Segment and consolidated net loss	$	(47,584)	$	(48,503)

^(a)Other segment expenses includes reimbursements receivable for research and development tax and expenditure credits of $1,238,000 (2024: $3,499,000), depreciation of $2,291,000 (2024: $2,771,000), amortization of $175,000 (2024: $59,000) and share-based compensation expenses (see Note 11), respectively.